Assessment of long-term toxicities of imatinib in CML: Experience from a tertiary care cancer centre in south India. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...
Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...
Which bike is best between Shema E-Vehicle Bold vs Zontes GK350? Shema Bold has out rated Zontes GK350 on all the rating factors. Which bike is cheaper Shema E-Vehicle Bold vs Zontes GK350? The Shema ...
5 questions HR legally cannot ask you in a job interview — and what to do if they're brought up Trans Mountain proceeding with first of three expansions of oil pipeline Elon Musk warns a new social ...
Experts explore the evolving landscape of chronic lymphocytic leukemia treatment, highlighting targeted therapies, MRD strategies, and future innovations. In this episode of Treating Together, host ...
This is a syndicated post stub. Oncology Nurse Advisor, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform ...
Retreatment with venetoclax and rituximab in CLL patients achieved 100% response rates and prolonged progression-free survival. Median progression-free survival was 9.5 years from initial treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results